1. Lysophosphatidylcholine-based liposome to improve oral absorption and nephroprotective effects of astaxanthin.
- Author
-
Ghosh A, Banik S, Suzuki Y, Mibe Y, Rikimura S, Komamoto T, Kuromi K, Yamada K, Sato H, and Onoue S
- Subjects
- Rats, Animals, Xanthophylls, Particle Size, Phosphatidylcholines, Liposomes, Lysophosphatidylcholines pharmacology
- Abstract
Background: The present study was aimed to develop astaxanthin (AX)-loaded liposomes by the utilization of soybean phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) to improve the nutraceutical properties of AX. AX-loaded liposomes consisting of PC (PC/AX) and LPC (LPC/AX) were evaluated in terms of particle size distribution, morphology, release characteristics, pharmacokinetic behavior, and nephroprotective effects in a rat model of acute kidney injury., Results: PC/AX and LPC/AX had uniform size distributions with a mean particle size of 254 and 148 nm, respectively. Under pH 6.8 conditions, both liposomes exhibited improved dissolution behavior of AX compared with crystalline AX (cAX). In particular, LPC/AX showed a sevenfold higher release of AX than PC/AX. After the oral administration of LPC/AX (33.2 mg AX kg
-1 ) to rats, there was a significant increase in systemic exposure to AX, as evidenced by a 15-fold higher AUC0-24 h than PC/AX. However, the oral absorption of AX in the cAX group was negligible. Based on the results of histological analysis and measurement of plasma biomarkers, LPC/AX exhibited improved nephroprotective effects of AX in the rat model of kidney injury., Conclusion: From these observations, a strategic application of the LPC-based liposomal approach might be a promising option to improve the nutraceutical properties of AX. © 2022 Society of Chemical Industry., (© 2022 Society of Chemical Industry.)- Published
- 2023
- Full Text
- View/download PDF